Archives
-
GSK-923295: Reading Mitotic Phenotypes
2026-09-05
GSK-923295 is a CENP-E inhibitor that enables researchers to separate motor-dependent chromosome congression defects from centromere-architecture phenotypes. This article connects CENP-E biochemistry, CTCF-dependent centromere maintenance, and assay design for more interpretable cancer research.
-
Halazone: Redox Logic for Translational Research
2026-09-04
Halazone is more than a water disinfection agent: its hypochlorous-acid chemistry creates a useful bridge between oxidative microbiology and sodium-channel electrophysiology. This article examines the mechanistic evidence, experimental parameters, translational limits, and strategic opportunities for antimicrobial resistance research and neurophysiology.
-
Topotecan: From Topo I Trapping to Assay Design
2026-09-04
Topotecan and SKF104864 connect topoisomerase I trapping with replication stress, apoptosis, and schedule-sensitive cancer research. This guide translates clinical evidence in recurrent SCLC into a practical framework for glioma and pediatric tumor assays.
-
Firefly Luciferase mRNA: Workflow & Troubleshooting
2026-09-03
Build more consistent transfection controls, gene expression assays, and in vivo imaging studies with a capped, modified reporter transcript. This guide translates the product’s design into practical workflows while showing how luciferase readouts can support, but not replace, deeper evaluation of mRNA-LNP delivery and immune memory.
-
EZ Cap™ Firefly Luciferase mRNA Workflow Guide
2026-09-03
Build faster, more reproducible reporter workflows with Cap1-capped, poly(A)-optimized luciferase mRNA. This guide connects delivery optimization, translation measurement, viability controls, and in vivo imaging with practical troubleshooting and evidence-based experimental design.
-
SD 169: p38 MAPK Workflow Guide
2026-09-02
SD 169 (indole-5-carboxamide) gives researchers a focused way to interrogate p38α/β signaling across inflammatory, metabolic, apoptotic, and nerve-repair models. This guide turns its ATP-competitive profile into practical assay workflows, controls, optimization steps, and troubleshooting strategies.
-
USP7–PKM2 Metabolic Control in Severe Acute Pancreatitis
2026-09-02
This 2025 study identifies USP7 as an upstream regulator of macrophage polarization in severe acute pancreatitis through PKM2-dependent metabolic reprogramming. Its combination of genetic perturbation, metabolic flux analysis, protein-interaction assays, and pharmacological rescue supports PKM2 as a mechanistic link between deubiquitination, glycolytic behavior, and pancreatic inflammation.
-
Lactate–GPR81 Signaling and Insulin-Independent Uptake
2026-09-01
The reference study identifies L-lactate as an insulin-independent regulator of skeletal-muscle glucose uptake and defines a GPR81–FARP1–RAC1 pathway that promotes GLUT4 translocation. Its combination of metabolic perturbation, receptor genetics, pharmacological activation, exercise analysis, and human genetic data provides a framework for studying glucose control beyond canonical insulin–AKT signaling.
-
Annexin V-FITC/7-AAD Apoptosis Kit Guide
2026-09-01
The Annexin V-FITC/7-AAD Apoptosis Kit provides a rapid two-parameter readout for viable, apoptotic, and membrane-compromised cells in cell viability assay and cytotoxicity assay workflows. It is appropriate for endpoint apoptosis and necrosis detection by flow cytometry or fluorescence microscopy, but it should not be used alone to establish a signaling mechanism or to interpret unvalidated sample types.
-
ATRA Sensitizes Ovarian Cancer to PARP Inhibition
2026-08-31
The reference study identifies all-trans retinoic acid (ATRA) as a clinically relevant strategy for reducing cisplatin-induced resistance to PARP inhibitors in epithelial ovarian cancer. Its central mechanistic contribution is linking the resistant phenotype to an NAD+-associated signature involving ALDH1A1, NAMPT, PARP1, and CHK1, providing a rationale for sequential cisplatin, ATRA, and niraparib treatment.
-
RP3-340N1.2, IL-6, and NSCLC Progression
2026-08-31
This study identifies the lncRNA RP3-340N1.2 as a post-transcriptional regulator of IL-6 mRNA stability in non-small cell lung cancer. Its knockdown enhances ZC3H12A-associated IL-6 mRNA degradation, reduces tumor-cell proliferation and migration, and weakens tumor-promoting communication involving macrophages.
-
Trypsin-Responsive Nanomedicine for Acute Pancreatitis
2026-08-30
Wang and colleagues developed a mesenchymal-stem-cell-membrane-coated mesoporous organosilica nanoparticle that targets injured pancreatic acinar cells and releases BAPTA-AM after trypsin-mediated scaffold cleavage. In a mouse model, this design reduced intracellular calcium overload, suppressed inflammatory and necrotic signaling, improved pancreatic biomarkers, and increased survival, while also illustrating how disease-specific enzymatic activation can improve precision drug delivery.
-
2'-O-Methyladenosine in Purine Assays
2026-08-29
Use 2'-O-Methyladenosine as both a defined nucleoside input for cell experiments and an analytical standard for sensitive purine metabolomics. A matrix-aware UHPLC–MS/MS workflow adds practical advantages for RNA modification nucleosides, transport studies, and nucleoside analog research.
-
JSH-23: Mechanism of an NF-κB Inhibitor
2026-08-28
JSH-23 is a small-molecule NF-κB inhibitor that blocks p65 nuclear localization and DNA binding without preventing IκB degradation. Its reported activity in LPS-stimulated macrophages and a cisplatin-induced acute kidney injury model supports its use in inflammation research and NF-κB signaling pathway study.
-
HMGCS2, LysoPC, and Pulmonary Fibrosis
2026-08-28
Yang et al. identify injured type II alveolar epithelial cells as a major source of LysoPC accumulation in bleomycin-induced pulmonary fibrosis and show that these lipids activate lung fibroblasts. The study connects epithelial HMGCS2 loss with impaired lipid degradation through the PPARα–CPT1A/CPT2 axis, offering a mechanistic framework for lipid-focused fibrosis research.